Clinical Trials Market , Competitive Landscape and Market Poised for Rapid Growth by 2030
Clinical Trials Market Overview
Clinical trials, also known as
clinical research studies, are studies conducted under proper guidance of
experts regarding the efficacy, performance, and effects of experimental and
novel medications, treatments, and vaccines. These methods are used for testing
and gauging the performance of medications which can work on certain groups of
patients or patients with rare diseases. Analysts at Market Research Future
(MRFR) predict the global clinical trials market to expand at a phenomenal pace
from 2022 to 2030.
The global clinical trials market
is poised to reach a stellar size by 2030. It can exhibit a CAGR of 5.70% from
2022 to 2030 (forecast period). It stood at USD 47,500 Million. Rise in
globalization and development of novel drugs are major trends in the market.
Rising prevalence of chronic diseases has induced the need for clinical trials
which can be used in testing new formulations. Patent expiry of blockbuster
drugs is likely to increase the scope for the market over the forecast period.
Other pertinent drivers include rising demand for contract research
organizations (CROs), evolution of technology, and personalized medicine for
treatment of chronic maladies.
The market growth is primarily relied on the key factors,
including the increasing prevalence of chronic and long-term diseases coupled
with increasing investment in the R&D sector globally. In addition to this,
industrialization has led to increased disposable income, globalization, and
increased awareness about the health and availability of several key and
important drugs. These factors are driving growth of the global Clinical Trials Market. However, lack of a skilled and trained
workforce is restraining growth of the market. Also, high cost, stringent
regulations, and unfavorable government policies are hampering growth of
market.
Market Segmentation
The global clinical trials market has been segmented based
on phase, study design, indication, end users, and region.
Based on the phase, the market has been segmented into phase
I, phase II, phase III, and phase IV. Among these, the phase III trial segment
has been assessed to lead the market as the largest segment, owing to its high
value in the healthcare sector, as well as its comparatively superior
effectiveness. Phase I trial segment has been expected to grow at the fastest
growth rate during the forecast period, owing to the increase in its
applications in investigative new drug (IND) sector, technological
advancements, and the rising government initiatives to improve the healthcare
sector in emerging economies.
Based on the study design, the global clinical trials market
has been segmented into expanded access interventional, and observational.
Based on indication, the trials market has been segmented
into autoimmune/inflammation, cardiovascular, central nervous system (CNS)
condition, diabetes, obesity, oncology, pain management, and others.
Based on the end-user, the market is segmented into dental
hospitals & clinics, dental institutes, and dental academic and research
institutes.
Based on the region, the market has been segmented into the
Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA).
Regional Analysis
Asia Pacific (APAC), North
America, Europe, and the Middle East & Africa (MEA) are regions taken into
consideration in the compilation of the global clinical trials market report.
The Americas can be the leading
region in the market due to inclination towards development of new products,
huge patient population, and large number of pharmaceutical companies. Rising
cases of cancer, diabetes, and other maladies are likely to induce the market
demand during the forecast period. According to the National Cancer Society,
close to 63,340 cases of kidney cancer were registered in the U.S. alone in
2018.
The Europe region is expected to
display a massive growth rate during the forecast timespan due to large
prevalence of chronic diseases and large expenditure on research and
development by the pharmaceutical industry. Supportive regulations for
fostering growth of new medicines via clinical trials can bode well for the
regional market growth.
The APAC market is predicted to
exhibit to expand at a rapid pace due to government support regarding
establishment of R&D hubs, supportive government policies, lax regulations,
and increasing prevalence of rare diseases. Countries with subsidies such as
Australia, India, and China as well as low operational costs are attractive
regions for primary investment for large pharmaceutical and biopharmaceutical
companies.
Lastly, the MEA region has the
lowest market share due to a paucity of shared scientific knowledge, small
clinical trial centers, and ill-equipped technical centers.
Competitive Analysis
Major industry participants in
the global clinical
trials market Players include Eli Lilly and Company, Quintiles IMS,
Clinipace, Charles River Laboratories, Laboratory Corporation of America,
Pfizer, SGS SA, ICON plc, Paraxel International Corporation, Novo Nordisk A/S,
and others. Pharmaceutical companies are allying with CROs for expediting the
research and development of blockbuster drugs.
At
Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99
Hudson Street, 5Th Floor,
New
York, New York 10013
United
States of America
+1
628 258 0071
Email:
sales@marketresearchfuture.com
.jpg)
Comments
Post a Comment